Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Is BPC-157 safe during pregnancy?

BPC-157 has not been shown safe in pregnancy. Human pregnancy evidence, approved prescribing information, and verified product-specific risk data are absent.

Why we wrote this. People asking about BPC-157 in pregnancy need a direct evidence-limit answer, not reassurance inferred from exclusions or a nonexistent prescribing label.

In this article (5 sections)
  1. There is no BPC-157 pregnancy safety study
  2. Trial exclusion is not evidence of safety or harm
  3. There is no BPC-157 prescribing label
  4. What to do if exposure has already happened
  5. What we do not yet know

BPC-157 has not been shown to be safe during pregnancy. There are no adequate human pregnancy data. The small body of human research does not answer questions about miscarriage or birth defects. It does not address fetal growth or preterm birth. Delivery complications and effects after birth are unstudied too[1]. A pregnant person should not interpret missing evidence as reassurance.

BPC-157 is also not an approved medicine with official prescribing information. There is no approved pregnancy section or verified formulation to consult. There is no standard dosage or regulator-reviewed risk assessment either. If you are pregnant or planning pregnancy, discuss any product sold as BPC-157 with a qualified healthcare professional. Our BPC-157 overview explains the wider evidence gap.

There is no BPC-157 pregnancy safety study

A 2026 systematic review searched Embase, PubMed, the Cochrane Library, and ClinicalTrials.gov for human BPC-157 research through 1 June 2026. It found only three reports with 30 participants in total. Two reports covered 28 people treated for knee pain or interstitial cystitis; the third was a two-person intravenous safety pilot. The reports were uncontrolled and judged poor quality. They produced evidence of very low certainty[1]. None was a pregnancy study.

The fact that those small reports did not identify treatment-related adverse events does not establish pregnancy safety. Thirty participants are far too few to detect uncommon harms. The participants were not studied for pregnancy outcomes, and the products and routes differed. A safety observation in two adults cannot answer whether an exposure affects an embryo, fetus, placenta, pregnant patient, or breastfed infant.

Trial exclusion is not evidence of safety or harm

The registered Phase 1 study NCT02637284 planned to assess an oral BPC-157 product in healthy adults. Its eligibility criteria required a negative pregnancy test and excluded pregnant or lactating women[2]. That exclusion means the proposed study was not designed to produce pregnancy evidence. It does not show that investigators observed pregnancy harm, and it does not show that exposure is safe.

The same registry record has an unknown status and was last updated in 2015. It has no posted results[2]. A study plan cannot be treated as a completed safety result. Even if results from the planned healthy-adult study became available, pregnancy would remain a separate population requiring its own evidence.

There is no BPC-157 prescribing label

The brief behind this question refers to a label, but that premise is incorrect. The US Department of Defense's Operation Supplement Safety program describes BPC-157 as an unapproved drug and notes that it is not in the FDA's approved-drug database[3]. Products sold online or through unapproved channels do not acquire an FDA-reviewed pregnancy section simply because a seller provides directions or calls a document a label.

Product identity adds another layer of uncertainty. FDA says compounded drugs containing BPC-157 may present immunogenicity risks for some routes and can be difficult to characterize because of peptide-related impurities and active-ingredient complexity. The agency says it has no or only limited safety information for the proposed routes and lacks enough information to know whether the drug would harm humans[4]. This warning is not pregnancy-specific, but it shows why evidence about a named peptide cannot automatically validate a particular vial, capsule, or compounded preparation.

What to do if exposure has already happened

An exposure is a reason to get individualized advice, not a reason to assume that harm has occurred. CDC advises people who are pregnant or planning pregnancy to speak with a healthcare provider before starting or stopping medicines. It also notes that pregnancy safety information is limited even for many approved medicines[5]. BPC-157 has the additional problems of being unapproved and having uncertain product identity.

Tell the clinician the product name, seller or pharmacy, route, dates of use, and any lot or ingredient information that remains on the packaging. Bring the container or clear photographs if possible. That information may help a clinician or poison information service assess the exposure, but it cannot turn an unverified product into a known formulation. Seek urgent medical care for severe or rapidly worsening symptoms rather than waiting for online advice.

What we do not yet know

Human research has not established a safe pregnancy exposure, a risk level by trimester, placental transfer, effects on fetal development, pregnancy outcomes, or safety during breastfeeding. There is also no validated product-specific label that closes those gaps. Animal or laboratory findings about tissue repair cannot supply the missing human reproductive evidence.

The practical answer is therefore narrow: BPC-157 cannot be called safe during pregnancy on current evidence. A clinician can help assess an actual exposure and the condition for which the product was being used. The BPC-157 safety section covers other known limits, but it does not provide pregnancy clearance.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Is BPC-157 safe during pregnancy?

BPC-157 has not been shown to be safe during pregnancy. No adequate human pregnancy study has established effects on the pregnant patient, fetus, birth outcomes, or child development.

Does BPC-157 have a pregnancy warning on its label?

There is no approved BPC-157 prescribing label. Seller directions or product stickers are not regulator-reviewed prescribing information and do not provide a validated pregnancy risk assessment.

Were pregnant people included in BPC-157 trials?

The registered Phase 1 study excluded pregnant and lactating women and has no posted results. Exclusion means the study could not answer the pregnancy question. It is not evidence that BPC-157 is safe or harmful in pregnancy.

What if I used BPC-157 before knowing I was pregnant?

Contact a qualified healthcare professional for an individualized assessment. Share the product, route, dates, packaging, and any symptoms. An exposure does not prove harm, but the evidence is too limited for online reassurance.

Sources

  1. [1]Poolton, Minett, and Kazmi (2026): Human evidence for BPC-157, a systematic review of efficacy and safetyTier 2 · expert↩
  2. [2]ClinicalTrials.gov: NCT02637284 safety and pharmacokinetics study recordTier 1 · primary↩
  3. [3]US Department of Defense OPSS: BPC-157 is an unapproved drugTier 1 · primary↩
  4. [4]FDA: Certain bulk drug substances for compounding may present significant safety risksTier 1 · primary↩
  5. [5]CDC: Medicine and pregnancyTier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars